Tollys focuses on innate immunity and the biology and modulation of the Toll‑like receptor 3 (TLR3). The company discovered and patented a family of TLR3 agonists and selected TL‑532, a structurally defined 70 base-pair double-stranded RNA produced synthetically, as its lead candidate. TL‑532 is highly specific to the TLR3 receptor, a feature the company says differentiates it from other TLR3 agonists tested in clinical trials. Tollys is using financing to support preclinical development of TL‑532 and to prepare for clinical development by late 2021/early 2022. The company has a staff of ten and has raised a total of €6.0M from private investors. Founded in 2015, Tollys intends to advance TL‑532 through regulatory toxicology and preclinical studies toward clinical entry. Tollys is a biopharmaceutical company focused on innate immunity and the biology and modulation of the Toll-like receptor 3 (TLR3). The company is advancing TL-532, a structurally defined double-stranded RNA produced synthetically and highly specific to the TLR3 receptor, as a new cancer immunotherapy. Founded in 2015 by senior scientists from the European Cancer Research Center of Lyon (CRCL) and the Centre Léon Bérard, the company is led by CEO Vincent Charlon and is based in Lyon, France. Tollys has ten staff and will use proceeds from its recent financing to manufacture TL-532 and to launch regulatory safety studies required before entry into clinical trials in bladder cancer by late 2021/early 2022. Financially, the company closed a €2.3m Series A and has raised €6.4m (€6.8M) in total since founding.

Total raised

$4M

Funding rounds

3

Latest round

Debt Financing

Latest activity

Jul 2020